Modern Treatment Approaches in Child and Adolescent Psychoses: integrative pharmacogenetic and neuroimagistic correlations
Poster B76, Friday, October 21, 11:30 am - 1:00 pm, Le Baron
Laura Nussbaum1, Lavinia Hogea1, Nicoleta Andreescu1, Liliana Nussbaum2, Maria Puiu1; 1University of Medicine and Pharmacy V. Babes Timisoara Romania, 2Mental Health Department for Children and Adolescents Timisoara
Introduction: We approach the theme of modern treatment strategies and the implication of different strategies in the management of child psychoses. Objectives: to analyze the effectiveness of modern pharmacogenetic testing, also in correlation with specific neurobiological and neuroimagistic markers, for an tailored, personalized treatment in psychosis; Methods: Research was conducted 2010-2015 on 150 children with psychosis – 75 children-G1, who benefited in choosing the pharmacotherapy from pharmacogenetic testing and 75 without-G2 and 120 children UHR for psychosis – 60 benefited of pharmacotherapy after pharmacogenetic testing and 60 without testing. Patients were evaluated through MRSpectroscopy at baseline and after pharmacotherapy. The efficacy of the chosen therapy in correlation with the pharmacogenetic testing was evaluated through the mean change in the PANSS scores, in the CGI-S/I, CGAS, UKU and through the change registered for the relevant MRspectroscopy metabolites. The pharmacogenetic testing was done through genotyping the SNP – Single Nucleotide Polymorfisms, after DNA extraction. The CYP*allelic variants genotypes were determined by measuring allele-specific fluorescence using the software for allelic discrimination. Results: Results, show significant differences of the clinical scores between groups: for subjects who benefited of pharmacogenetic testing, the PANSS, the global functioning scores prove a higher clinical improvement and lower UKU side effects scores and also improvement concerning the MRSpectroscopy dosed metabolites values. Conclusions: Our research was a proof, sustaining the use of the pharmacogenetic testing in clinical practice and the value of investigating relevant neurobiological and neuroimagistic markers for a tailored therapy in child psychosis as a fruitful pathway of intervention.
Topic Area: Psychopharmacology